Tiseo M; Gridelli C; Cascinu S; Crino L; Piantedosi FV; Grossi F; Brandes AA; Labianca R; Siena S; Amoroso D; Belvedere O; Valentino B; Bearz A; Venturino P; Ardizzoni A, An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy, «LUNG CANCER», 2009, 64, pp. 199 - 206 [replica/breve intervento]
Tibaldi C; Giovannetti E; Tiseo M; Danesi R; Leon LG; Bartolotti M; D'Incecco A; Erozenci AL; Falcone A; Peters GJ; Ardizzoni A, Correlation between cytidine deaminase (CDA) genotype and clinical outcome/toxicity in advanced non-small cell lung cancer (NSCLC) patients treated with gemcitabine/platinum-based chemotherapy, «JOURNAL OF THORACIC ONCOLOGY», 2009, 4, pp. S553 - S553 [abstract]
Tiseo M; Bordi P; Bortesi B; Azzoni C; Campanini N; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Rindi G; Bordi C; Ardizzoni A, ERCC 1/BRCA1 PROTEIN EXPRESSIONS AND ERCC1/XPD/XRCC1-3 GENE POLYMORPHISMS AS PREDICTOR FACTORS OF OUTCOME IN STAGE IIIB-IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED IN FIRST-LINE CHEMOTHERAPY WITH OR WITHOUT CISPLATIN, «ANNALS OF ONCOLOGY», 2009, 20, pp. 1695 - 1703 [abstract]
Tiseo M; Bordi P; Bortesi B; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Bordi C; Ardizzoni A, ERCC 1/BRCA1 protein expressions and ERCC1/XPD/XRCC1-3 gene polymorphisms as predictor factors of outcome in stage III-IV non-small cell lung cancer (NSCLC) patients treated in first-line chemotherapy with or without cisplatin, «JOURNAL OF THORACIC ONCOLOGY», 2009, 4, pp. S402 - S402 [abstract]
La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Ardizzoni A; Tiseo M; Capelletti M; Goldoni M; Tagliaferri S; Mutti A; Fumarola C; Bonelli M; Generali D; Petronini PG, Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines, «BIOCHEMICAL PHARMACOLOGY», 2009, 78, pp. 460 - 468 [replica/breve intervento]
M. Tiseo; M. Bartolotti; F. Gelsomino; Ardizzoni A, First LineTreatment in advanced non small-cell lung cancer: the emerging role of the histologic subtype, «EXPERT REVIEW OF ANTICANCER THERAPY», 2009, 9, pp. 425 - 435 [replica/breve intervento]
Gridelli C; Bajetta E; De Marinis F; Crino L; Barni S; Ardizzoni A; Gebbia V; Adamo V; Morena R; Caprioli A, First-line treatment of over 1000 Italian patients affected by stage IIIB-IV NSCLC: results from the observational "Sun" (Survey on the Lung Cancer Management) study, «JOURNAL OF THORACIC ONCOLOGY», 2009, 4, pp. S453 - S453 [abstract]
A. Musolino; M. Panebianco; E. Zendri; M Santini; S. Di Nuzzo; Ardizzoni A, Hypertriglyceridaemia with bexarotene in cutaneos T cell Lymphoma: the role of Omega-3 fatty acids, «BRITISH JOURNAL OF HAEMATOLOGY», 2009, 145, pp. 84 - 86 [replica/breve intervento]
S. Tanzi; M. Tiseo; E. Internullo; G. Cacciani; R. Capra; P. Carbognani; M. Rusca; G. Rindi; Ardizzoni A, Localized malignant pleural mesothelioma : report of two cases, «JOURNAL OF THORACIC ONCOLOGY», 2009, 4, pp. 1038 - 1040 [replica/breve intervento]
Barni S; Bajetta E; De Marinis F; Crino L; Ardizzoni A; Caprioli A; Favaretto A; Giannicola R; Filippelli G; Gridelli C, Medical treatment choices of over 1000 Italian patients affected by stage IIIB-IV NSCLC in routine clinical practice: results from the observational "SUN" (Survey on the lUng cancer maNagement) study on behalf of SUN study Group, «EUROPEAN JOURNAL OF CANCER. SUPPLEMENT», 2009, 7, pp. 515 - 516 [abstract]
Franciosi V; Sgargi P; Melegari E; Bozzani F; Gnappi D; Michiara M; Vasini G; Salvagni S; Bacchini GP; Ghisoni F; De Lisi V; Ardizzoni A, PALLIATIVE CARE FOR TERMINALLY-ILL CANCER PATIENTS RESIDENT IN PARMA PROVINCE: RATES OF HOSPITALISATION, USE OF HOME CARE AND HOSPICE SERVICES AND PRESCRIPTION OF CHEMOTHERAPY NEAR TO DEATH, «ANNALS OF ONCOLOGY», 2009, 20, pp. 1 - 1 [abstract]
Zilembo N; Gridelli C; De Marinis F; Crino L; Ardizzoni A; Caprioli A; Pela R; Marangolo M; Buscarino C; Barni S, SURVIVAL OF ITALIAN PATIENTS NEWLY DIAGNOSED STAGE IIIB-IV NSCLC STARTING PHARMACOLOGICAL TREATMENT: 1-YEAR FOLLOW UP RESULTS FROM THE SUN (SURVEY IN THE LUNG CANCER MANAGEMENT) OBSERVATIONAL STUDY, «ANNALS OF ONCOLOGY», 2009, 20, pp. 1 - 1 [abstract]
Tiseo M; Gelsomino F; Bartolotti M; Barili MP; Ardizzoni A, Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report, «LUNG CANCER», 2009, 65, pp. 251 - 253 [replica/breve intervento]
Parra HJS; Ippolito M; Tiseo M; Cosentino S; Pumo V; Bordonaro R; Latteri F; Ardizzoni A; Bortesi B; Spadaro P, Usefulness of 18FDG-positron emission tomography for early prediction of response in non-small cell lung cancer (NSCLC) patients treated with erlotinib: results of a pilot study, «JOURNAL OF THORACIC ONCOLOGY», 2009, 4, pp. S375 - S376 [abstract]
Cascinu S; Berardi R; Salvagni S; Beretta GD; Catalano V; Pucci F; Sobrero A; Tagliaferri P; Labianca R; Scartozzi M; Crocicchio F; Mari E; Ardizzoni A, A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation, «BRITISH JOURNAL OF CANCER», 2008, 98, pp. 71 - 76 [replica/breve intervento]
